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Two recent North American studies have shown that completion of 5-fluorouracil (5FU)-based adjuvant chemotherapy is a major
prognostic factor for the survival of elderly stage III colon cancer patients. The aim of the present study was to confirm this finding in a
population-based series from Australia. The study cohort comprised 851 stage III colon cancer patients treated by surgery alone and
461 who initiated the Mayo chemotherapy regime. One-third of patients who initiated chemotherapy failed to complete more than
three cycles of treatment. Independent predictors for failure to complete were treatment in district or rural hospitals, low
socioeconomic index and treatment by a low-volume surgeon. Patients who failed to complete chemotherapy showed worse
cancer-specific survival compared not only to those who completed treatment (HR¼2.24; 95% confidence interval (CI) (1.66–3.03),
Po0.001) but also to those treated by surgery alone (HR¼1.37; 95% CI (1.09–1.72), P¼0.008). The current and previous studies
demonstrate the importance of completing adjuvant 5-FU-based chemotherapy for colon cancer. Further prospective studies are
required to identify better the physiological and socioeconomic factors responsible for failure to complete chemotherapy so that
appropriate improvements in health service delivery can be made.
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Randomised controlled trials conducted in the 1980s demonstrated
that 5-fluorouracil (5FU)-based chemotherapy resulted in a 10%
absolute improvement in 5-year survival for stage III CRC patients
(Moertel et al, 1990). As a result of these trials the National
Institutes of Health recommended in 1990 the routine adminis-
tration of FU-based adjuvant chemotherapy for medically fit
patients with completely resected stage III CRC (NIH Consensus
Conference, 1990). In the early 1990s, adjuvant chemotherapy with
5FU was used in combination with levamisole or leucovorin and
regimes varied from 6 to 12 months in length. By 1995, the
standard of care in many countries, including Australia, had
become the Mayo regime of intravenous 5FU/leucovorin for 6
months.
Randomised controlled clinical trials generally analyse the
benefits of treatment in patient cohorts with few comorbidities.
Participants in the earlier randomised clinical trials for CRC were
highly selected and most patients were aged o70 years. These do
not accurately represent all patients who may ultimately become
candidates for treatment in the general population. Nevertheless,
several reports have recently documented a similar degree of
survival benefit from 5FU in older patient groups from a
population-based setting (Iwashyna and Lamont, 2002; Sundararajan
et al, 2002; Jessup et al,2 0 0 5 ;D o b i eet al,2 0 0 6 ;N e u g u tet al,2 0 0 6 ) .
These results support earlier evidence from randomised control
trials and clearly establish benefit from 5FU-based adjuvant
chemotherapy in stage III colon cancer.
Two recently published studies using the SEER database
examined the early termination of adjuvant chemotherapy regimes
in the elderly population in relation to survival (Dobie et al, 2006;
Neugut et al, 2006). These papers reported that patients who failed
to complete 5FU-based chemotherapy showed significantly worse
survival compared to those who completed the treatment.
Confirmation of the findings with respect to completion of
treatment has important implications for the delivery of effective
healthcare to patients with colon cancer. This paper examines the
effect on survival of failure to complete adjuvant chemotherapy in
a population-based cohort that includes patients of all ages and
who were treated exclusively with the Mayo regime.
METHODS
Study population
Pathology records from the four major hospitals in Western
Australia were used to identify patients diagnosed with CRC
during the period 1994–2001 inclusive. The pathology services at
these hospitals also process specimens from minor district and
country hospitals. This patient list was crosschecked with the
Cancer Registry of Western Australia. Approximately 90% of all
CRC patients who underwent surgical resection were identified for
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sthe population of Western Australia, comprising 1.8–2 million
people over the study period. Tumour stage was classified
according to the current American Joint Committee on Cancer
guidelines (AJCC Cancer Staging Manual, 6th edn, 2002). A total of
2024 patients with CRC fulfilled the criteria for stage III CRC and
1404 of these had colonic carcinoma. All cases showed clear
margins (R0 resections). Rectal carcinomas were defined as
originating within 12cm of the anal verge and these were excluded
from the analysis. Information on pathological variables was
obtained from the histopathology reports. Perforation was
considered to be present if noted by the surgeon at operation or
on histopathological review of the specimen. Clinical records were
used to classify tumours presenting with obstruction. Anatomical
site of the tumour was crosschecked with information from
admission and procedure records. Colonic cancers were subclassi-
fied as being proximal or distal to, and including, the splenic
flexure.
Surgical caseload was defined as low (p10), medium (11–50)
and high (450) for stage II and III colon cancer resections over
the 8-year study period. Hospitals were classified as teaching
(university affiliated), private (fee for service), district (non-
teaching and non-private institutions located in the metropolitan
region of Perth) or rural (non-metropolitan). Each patient’s post
code address was obtained from the West Australian Cancer
Registry database and this was linked to Socio-Economic Indexes
for Areas (advantaged/disadvantaged and economic resources)
obtained from the 2001 Australian census (Australian Bureau of
Statistics, 2001). Patients with an advantaged/disadvantaged score
of 1 were the most deprived quintile in socioeconomic terms,
whereas a score of 5 corresponds to the most advantaged group.
Patients with a score of 1 for economic resources had the least
financial resources, whereas those with a score of 5 had the most.
Ethics approval for the project was obtained from individual
hospital Human Research Ethics Committees, the University of
Western Australia and the Confidentiality of Health Information
Committee.
Adjuvant chemotherapy
Procedure codes from the morbidity database of the Data Linkage
Unit, Health Department of Western Australia, were used to
identify patients who began chemotherapy within 120 days of
resection. The adjuvant chemotherapy regimes used in Western
Australia varied during the study period. Cases were individually
reviewed using hospital records and only those patients (n¼461)
who received the Mayo regime were included in the study. A total
of 92 patients who received the Roswell or other regimes were
excluded. Patients who received chemotherapy for a recurrence
were also documented (n¼150). Less than 15 doses administered
were defined as p3 cycles (n¼156) and 16–30 doses as 4–6 cycles
(n¼305). Therefore, the study cohort (n¼1312) comprised 851
patients treated by surgery alone and 461 who initiated the Mayo
chemotherapy regime.
Survival data
Mortality data were obtained from the Death Registry of the Health
Department of Western Australia. Death reports were reviewed
individually and classified as death due to colon cancer or from
other causes. The perioperative mortality rate (4.8%) was defined
as death within 30 days of surgery. At the end of the study period,
155 (11.8%) patients died from unrelated causes and 657 (50.1%)
from recurrence of colonic cancer. Of the 461 patients who
initiated adjuvant chemotherapy, three patients died as a result of
chemotherapy treatment (0.65%). Sepsis and pancytopaenia were
responsible for two deaths and one patient died of gastrointestinal
haemorrhage secondary to a duodenal ulceration. One other
patient died from a cerebrovascular accident while on chemo-
therapy 3 months after resection. Survival time was calculated
from the date of diagnosis to date of death from cancer or 1 March
2006, whichever came first. This enabled cancer-specific and
overall survival to be evaluated. The mean length of follow-up was
52 months and the median was 36 months (range 0–147 months).
Statistical analysis
Chi square analysis was used to identify factors influencing the
rates of chemotherapy initiation and completion. A multiple
logistic regression model in which each demographic, pathological
and clinical variable listed in Table 1 was adjusted for all others
was used to estimate odds ratios and 95% confidence intervals
(CIs) for independent predictors of chemotherapy initiation or
completion. Survival analysis was conducted using both unad-
justed Kaplan–Meier analysis and Cox proportional hazards
regression. The log-rank test was used to determine the
significance for Kaplan–Meier analysis. A Cox proportional
hazards regression model was developed for survival in which
each variable was adjusted for all others. Statistical significance
was deemed if Po0.05.
Table 1 Initiation of adjuvant chemotherapy for stage III colon cancer
patients according to demographic factors (n¼1312)
Characteristic
Percentage of total
cases
Rate of chemotherapy
initiation (%)
Total 100.0 35.1
Year of diagnosis
1994 11.2 16.3
a
1995 11.7 32.5
1996 13.7 33.9
1997 16.1 39.6
1998 13.7 40.7
1999 13.5 47.0
2000 10.1 39.4
2001 9.9 40.0
Age (years)
p55 16.8 52.5
b
56–65 21.8 52.1
66–75 32.4 31.1
X76 29.0 16.8
Sex
Male 51.6 37.0
Female 48.4 33.4
Advantage/disadvantage
1 22.0 33.6
2 23.3 36.5
3 18.8 32.9
4 18.5 35.6
5 17.4 39.6
Economic resources
1 22.2 32.5
2 23.1 34.0
3 17.6 32.6
4 19.1 40.2
5 18.0 39.3
Hospital
Teaching 46.0 31.8
b
District 11.2 21.1
Rural 14.3 33.3
Private 28.5 47.1
aPo0.025.
bPo0.0001.
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sRESULTS
In this population-based cohort, just over one-third of stage III
colon cancer patients initiated chemotherapy using the Mayo
regime (Tables 1 and 2). From 1997 to 2001, the rate remained
steady at approximately 40% of cases. This is probably reflective of
stabilisation of surgical referral and oncological practice following
the initial period of 5FU chemotherapy implementation. As
expected, chemotherapy use declined with increasing age. Patients
treated in private hospitals and those whose tumours were
detected by colonoscopy or sigmoidoscopy were more likely to
initiate chemotherapy. These same three factors were found in
multivariate analysis to be independent predictors for the
initiation of chemotherapy (Figure 1). None of the pathological
variables were associated with the commencement of chemo-
therapy.
The survival of patients who initiated chemotherapy is shown in
Table 3 according to the number of cycles received. Compared to
patients treated by surgery alone, those who received only one
cycle of chemotherapy showed significantly worse survival. A
trend for worse survival was also observed for patients treated with
two or three cycles. In contrast, patients treated with four, five or
six cycles showed better survival than those treated by surgery
alone. On the basis of these results and for this study, patients who
received 4–6 cycles were classified as having completed chemo-
therapy, whereas those treated with 1–3 cycles were deemed not to
have completed this treatment. The former group was estimated to
have a 30% survival advantage and the latter group a 40% survival
disadvantage compared to patients treated by surgery alone
(Table 3 and Figure 2).
Two-thirds of patients who initiated chemotherapy completed
4–6 cycles of treatment (Tables 4 and 5). Factors associated with
higher rates of completion were N1 nodal status, high surgeon
caseload, treatment in teaching and private hospitals and high
socioeconomic indices. Multivariate analysis revealed that inde-
pendent predictors for completion of chemotherapy were the type
of treatment hospital, high socioeconomic index and high surgical
volume (Table 6). Females showed a trend for less likelihood of
completion (P¼0.08).
DISCUSSION
Two recent studies using SEER data reported that stage III colon
cancer patients who failed to complete 5FU chemotherapy showed
worse survival compared to those who completed the regimen
(Dobie et al, 2006; Neugut et al, 2006). The present investigation of
an Australian population-based cohort of stage III colon cancer
Table 2 Initiation of adjuvant chemotherapy for stage III colon cancer
patients according to pathological and clinical factors (n¼1312)
Characteristic
Percentage of total
cases
Rate of chemotherapy
initiation (%)
Total 100.0 35.1
Pathology
Site
Proximal 53.5 33.0
Distal 46.5 37.5
Grade
Well/moderate 76.1 34.8
Poor 23.9 36.1
T stage
T1/T2 5.0 41.6
T3 71.0 35.8
T4 24.0 32.1
Nodal status
N1 64.9 34.2
N2 35.1 36.9
Vascular invasion
Absent 69.7 35.2
Present 30.3 35.0
Perineural invasion
Absent 87.7 34.3
Present 12.3 41.0
Perforation
Absent 91.8 35.1
Present 8.2 35.5
Mucinous
Absent 73.7 35.1
Present 26.3 35.4
Lymphocytic
response
Absent 85.7 34.4
Present 14.3 39.4
Clinical
Obstruction
Absent 86.2 35.4
Present 13.8 33.7
Colonoscopy or
sigmoidoscopy
Yes 56.9 40.2
a
No 43.1 28.5
Surgical case load
Low 13.8 32.0
b
Medium 47.4 31.2
High 38.8 41.1
aPo0.0001.
bPo0.002.
>76
66–75
56–65
<55
Private
District
Rural
Teaching
Yes
No
0.0 0.5 1.0 1.5 2.0 2.5
0.0 0.5 1.0 1.5 2.0 2.5
0.0 0.5 1.0 1.5 2.0 2.5
P<0.001
P<0.001
P=0.006
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Figure 1 Predictors for the initiation of 5FU adjuvant chemotherapy in
stage III colon cancer patients adjusted in multivariate analysis.
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sconfirms the findings of the North American groups. Moreover,
the current study also found that patients who initiated but did not
complete chemotherapy (1–3 cycles received) showed significantly
worse survival than patients treated by surgery alone (Table 3).
There were several differences in study design between the
current investigation and the North American reports. Patients of
all ages were included here, whereas only 465-year-old patients
were investigated previously. Despite the younger cohort, only
35% of patients initiated chemotherapy (Tables 1 and 2) compared
to 54 and 55% for the SEER-derived cohorts (Dobie et al, 2006;
Neugut et al, 2006). The completion rate for patients who initiated
chemotherapy in the present investigation (66%,Tables 4 and 5)
was comparable to the North American report (64%) from the
same study period (Neugut et al, 2006). Both were slightly lower
than the second North American report (78%), which investigated
an earlier study period, included both 12 and 6 month regimes and
presented 3-year cancer-specific mortality data (Dobie et al, 2006).
Although the present study had a smaller sample size, individual
patient records were reviewed for pathology, chemotherapy regime
and cause of death.
In spite of these minor differences in study design, all three
investigations have observed a significant survival advantage
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Figure 2 Kaplan–Meier survival analysis for stage III colon cancer
patients treated with surgery alone (0 cycles, light grey), 1–3 cycles
(incomplete chemotherapy, dark grey) or 4–6 cycles (complete chemo-
therapy, black) of 5FU adjuvant chemotherapy using the Mayo regime.
Log-rank test: P¼0.021 for incomplete chemotherapy vs surgery alone
Po0.0001 for complete chemotherapy vs surgery alone; Po0.0001 for
complete chemotherapy vs incomplete chemotherapy.
Table 3 Mortality hazard ratios according to number of completed cycles of adjuvant 5FU chemotherapy, multivariate-adjusted
Cancer-specific survival Overall survival
Chemotherapy (n) HR 95% CI P HR 95% CI P
None (851) 1.00 1.00
1–3 cycles (156) 1.37 1.09–1.72 0.008 1.09 0.88–1.35 NS
4–6 cycles (305) 0.67 0.54–0.83 o0.001 0.55 0.45–0.67 o0.001
1 cycle (68) 1.72 1.24–2.38 o0.001 1.26 0.93–1.71 NS
2 cycles (40) 1.19 0.79–1.80 NS 0.92 0.63–1.36 NS
3 cycles (48) 1.17 0.79–1.74 NS 1.04 0.73–1.48 NS
4 cycles (41) 0.74 0.46–1.20 NS 0.61 0.39–0.97 0.035
5 cycles (105) 0.77 0.56–1.07 NS 0.59 0.43–0.81 0.001
6 cycles (159) 0.53 0.39–0.72 o0.001 0.43 0.32–0.58 o0.001
CI¼confidence interval; 5FU¼5-fluorouracil; HR¼hazard ratio.
Table 4 Completion of adjuvant chemotherapy for stage III colon cancer
patients according to demographic factors (n¼305)
Characteristic Percentage of total cases Rate of completion (%)
Total 100.0 66.3
Year of diagnosis
1994 3.3 41.7
1995 9.2 68.0
1996 12.5 67.7
1997 20.0 66.3
1998 14.4 63.8
1999 15.4 69.3
2000 11.8 66.7
2001 13.4 72.0
Age (years)
p55 25.2 66.4
56–65 34.4 70.5
66–75 26.9 62.1
X76 13.4 64.1
Sex
Male 53.1 68.9
Female 46.9 63.3
Advantage/disadvantage
1 16.4 52.6
a
2 23.6 66.1
3 18.0 65.8
4 20.0 69.0
5 22.0 76.1
Economic resources
1 13.8 45.2
b
2 24.6 74.3
3 16.1 58.9
4 24.3 75.5
5 21.3 72.2
Hospital
Teaching 43.6 69.3
b
District 4.9 48.4
Rural 9.2 45.2
Private 42.3 73.3
aPo0.02.
bPo0.001.
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sassociated with the completion of chemotherapy. The survival
advantage was estimated at 33% (Table 3) and 21% (Dobie et al,
2006) compared to patients treated by surgery alone. When
patients who did not complete chemotherapy were used as the
reference group, the survival advantage was even greater at 47%
(Neugut et al, 2006) and 55% in the current investigation
(HR¼0.45; 95% CI (0.33–0.60), P¼0.005). Importantly, the same
pattern of survival advantage from the completion of chemo-
therapy was also observed by our group in a population-based
cohort of stage II colon cancer patients (unpublished). Using
patients treated by surgery alone as the reference group (n¼1362),
patients who completed chemotherapy (n¼142) showed a
significant survival advantage (HR¼0.63; 95% CI (0.41–0.96),
P¼0.03), whereas those who did not complete (n¼49) showed
worse survival (HR¼1.27; 95% CI (0.71–2.29), P¼0.42).
The predictors for initiation of chemotherapy were found in
multivariate analysis to be younger patient age, treatment in a
private hospital and preoperative colonoscopy or sigmoidoscopy
(Figure 1). The first two factors are likely to reflect patients with
lower comorbidities and higher socioeconomic status, respectively,
whereas the third factor may represent non-emergency presenta-
tion. Interestingly, none of the reported pathological variables was
predictive for the initiation of chemotherapy in stage III colon
cancer. District hospitals were defined here as non-teaching and
non-private institutions located in the metropolitan region of
Perth. Patients treated in these hospitals showed a two-fold lower
initiation rate for chemotherapy compared to teaching institutions,
suggesting deficiencies in access to oncology services.
Patients with greater levels of psychosocial support and financial
resources would be expected to show higher rates of chemotherapy
completion. This is supported by our findings that patients with a
high socioeconomic index or who were treated in teaching or
private hospitals showed higher rates of completion (Table 6).
Previous North American studies have shown that married status
is also predictive for the completion of chemotherapy (Dobie et al,
2006; Neugut et al, 2006). It is of concern that patients treated in
district and rural hospitals showed approximately half the rate of
chemotherapy completion compared to patients from teaching and
private hospitals (Table 6). There is clearly a need to identify the
underlying reasons leading to low initiation and completion rates
for the 25% of colon cancer patients treated in these centres so that
equality of health provision can be improved.
There are several current and commonly used 5FU regimes
ranging from protracted, continuous infusional 5FU delivery to
Table 5 Completion of adjuvant chemotherapy for stage III colon cancer
patients according to pathological and clinical factors (n¼305)
Characteristic
Percentage of
total cases
Rate of
completion (%)
Total 100.0 66.3
Pathology
Site
Proximal 47.2 62.1
Distal 52.8 70.3
Grade
Well/moderate 78.0 68.4
Poor 22.0 59.3
T stage
T1/T2 6.6 74.1
T3 71.1 65.2
T4 22.3 67.3
Nodal status
N1 67.2 70.4
a
N2 32.8 58.8
Vascular invasion
Absent 70.2 66.5
Present 29.8 65.5
Perineural Invasion
Absent 85.6 66.1
Present 14.4 66.7
Perforation
Absent 90.8 65.5
Present 9.2 73.7
Mucinous
Absent 73.4 66.1
Present 26.6 66.4
Lymphocytic
response
Absent 82.0 64.6
Present 18.0 66.2
Clinical
Obstruction
Absent 87.5 66.8
Present 12.5 62.3
Colonoscopy or sigmoidoscopy
Yes 69.2 70.3
b
No 30.8 58.4
Surgical case load
Low 11.5 60.3
c
Medium 35.1 55.2
High 53.4 78.0
aPo0.02.
bPo0.01.
cPo0.001.
Table 6 Predictors for completion of adjuvant 5FU chemotherapy,
multivariate-adjusted
Odds ratio 95% CI P
Age of diagnosis (years)
p55 1.00
56–65 0.98 0.55–1.76 NS
66–75 0.77 0.43–1.38 NS
X76 0.72 0.34–1.53 NS
Sex
Male 1.00
Female 0.68 0.44–1.05 0.08
Site
Proximal 1.00
Distal 1.37 0.84–2.24 NS
Surgical caseload
Low 1.00 0.007
Medium 0.88 0.45–1.72 NS
High 2.06 0.99–4.25 0.05
Advantage/disadvantage
1 1.00
2 1.83 0.96–3.50 NS
3 1.45 0.74–2.85 NS
4 1.62 0.81–3.23 NS
5 2.18 1.07–4.44 0.032
Economic resources
1 1.00
2 3.55 1.79–7.04 o0.001
3 1.61 0.80–3.23 NS
4 3.20 1.58–6.48 0.001
5 2.54 1.26–5.14 0.009
Hospital
Teaching 1.00
Private 0.91 0.52–1.58 NS
District 0.50 0.21–1.18 NS
Rural 0.40 0.20–0.79 0.009
CI¼confidence interval; NS¼nonsignificant.
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sbolus schedules. Protracted infusional regimes were developed to
maximise 5FU dose intensity. They have been found to be as
effective as the bolus regimens and less toxic, with less impact on
quality of life (Andre et al, 2003; Saini et al, 2003; Goyle and
Maraveyas, 2005). The Mayo and Roswell Park regimes are
commonly used in the USA and have different safety profiles.
The Mayo regime demonstrates more haematological but less
gastrointestinal toxicity compared with the Roswell Park regime.
In the UK and Europe the Lokich, LV5FU2 (de Gramont) or
QUASAR-type regimens are commonly used and have advantages
in terms of toxicity when compared with the Mayo regime, but
comparable survival rates (Goyle and Maraveyas, 2005).
The other major factor likely to result in failure to complete
chemotherapy is toxicity. It is well-documented that bolus
schedules of 5FU cause more severe leucopenia and stomatitis in
elderly patients, particularly in females (Milano et al, 1992; Meta-
analysis Group in Cancer, 1998; Zalcberg et al, 1998; Popescu et al,
1999; Tebbutt et al, 2000; Sloan et al, 2002; Chansky et al, 2005). In
agreement with these findings, the present study found that
females were less likely to complete adjuvant chemotherapy when
adjusted for other variables (Table 6), and we postulate this is due
to an increased incidence of toxicity. The retrospective nature of
this population-based study meant that information on treatment-
related toxicity was not available. The skill and experience of the
administrators of chemotherapy in the management of toxicities
and the capacity to provide psychosocial support to patients may
impact on the likelihood of a patient to complete their
chemotherapy regime.
Many of the toxicities that lead to the termination of 5FU
chemotherapy culminate around the time of the third cycle
(Tebbutt et al, 2000). Unfortunately, steady-state plasma 5FU levels
do not correlate with toxicity (Jodrell et al, 2001) and hence
pharmacokinetic monitoring is not used to identify patients who
are at increased risk of toxicity (Tebbutt et al, 2000). In randomised
controlled trials, dose reductions are common after the first two
cycles and 15–30% of patients fail to complete chemotherapy
(Wolmark et al, 1993; O’Connell et al, 1997; Poplin et al, 2005). The
relationship between systemic exposure and treatment efficacy has
not been demonstrated, however, and can only be ascertained by
conducting prospective randomised studies that compare a targeted
dose adjustment to a fixed dose (Milano et al, 1994).
A novel and unexpected observation from this study was that
stage III colon cancer patients who failed to complete chemother-
apy showed significantly worse cancer-specific survival compared
to patients treated by surgery alone (Table 3 and Figure 2). Dobie
et al (2006) did not find a significant difference in survival between
these two patient groups using 3-year cancer mortality data and
Neugut et al (2006) did not report this comparison. It is unlikely
that 5FU toxicity accounts for the increased mortality observed
here as recent trials have reported a chemotherapy-related death
rate of only 0.5% (Andre et al, 2004). The chemotherapy-related
death rate in this population-based cohort of stage III colon cancer
was 0.65% (3 out of 461). The 60-day mortality for patients that
initiated adjuvant chemotherapy was 0.4%. This is comparable to
published benchmark data for the safety of adjuvant chemotherapy
in colon cancer (Katopodis et al, 2004).
One possible explanation is that failure to complete chemotherapy
is indicative of high toxicity and this may in turn be associated with a
more aggressive tumour phenotype or impairment of the host
immune response. The CpG island methylator phenotype has worse
prognosis (Van Rijnsoever et al, 2003; Ward et al, 2003) and is linked
to the folate pathway (Kawakami et al, 2003). This latter pathway has
been implicated in toxicity to 5FU (Pinedo and Peters, 1988).
The results of the current study have relevance for the
introduction of new therapies for colon cancer. Oral fluoro-
pyrimidines (UFT and capecitabine) mimic protracted venous
infusional 5FU. Benefits of these agents include convenience,
elimination of risks from indwelling central venous catheters and a
different toxic profile. They are of comparable efficacy to the Mayo
regime but with less toxicity (Carmichael et al, 2002; Douillard
et al, 2002; Twelves et al, 2005). Toxicity profiles of FOLFOX and
FOLFIRI (Andre et al, 2004; O’Connell, 2004; Allegra and Sargent,
2005) may reduce the completion of these treatments, but fewer
cycles of these regimes may be as efficacious as the completed
Mayo regime. A recently published safety analysis of the XELOX
NO16968 study (Schmoll et al, 2007) found more frequent
treatment discontinuations with XELOX compared to the FU/LV
Mayo and Roswell Park regimes; however a comparable number of
patients completed 12 weeks of therapy (88 and 82%, respectively).
In conclusion, this study confirms two recent reports (Neugut
et al, 2006; Dobie et al, 2006) that stage III colon cancer patients
who fail to complete 5FU adjuvant chemotherapy show worse
survival than patients who completed this treatment. In addition,
the current study found that patients who do not complete
chemotherapy may in fact have worse survival than patients
treated by surgery alone. These results have implications for the
delivery of oncology services. Further research is needed to
identify factors that could increase both initiation and completion
rates of 5FU chemotherapy from colon cancer.
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